Fazle Husain

Fazle Husain is Head of US Healthcare at CVC Capital Partners, a global private equity firm with a network of 23 offices and over 400 employees throughout Europe, Asia and US. The CVC Group manages over $50 billion of assets. Prior to joining CVC Capital, Fazle was a Managing Director at Metalmark Capital from 2007-2016, and was responsible for leading their effort in healthcare. Before Metalmark Capital, he was with Morgan Stanley & Co. in the private equity business, where he spent 18 years. He has a successful track record of investing in healthcare companies for over 25 years, including investments in the healthcare service, medical device, specialty pharmaceuticals and healthcare information technology sectors. He has invested in and served on the Boards of several private and public companies including ExamWorks, MedRisk, Icario, Allscripts (MDRX), Cross Country Healthcare (CCRN), The Medicines Company (MDCO), Cardiac Pathways (sold to Boston Scientific), Suros Surgical (sold to Hologic), Healthstream (HSTM), Cytyc Corp (sold to Hologic), Aegis Sciences, and Vanguard Healthcare Systems (sold to Tenet). He was the Chairman of the Board of Healogics (2008-2014), and was the Chairman of the Board of Collagen Matrix (2014-2016).